Head-To-Head Review: Glaukos Corporation (GKOS) and The Competition
Glaukos Corporation (NYSE: GKOS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare Glaukos Corporation to related companies based on the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, earnings and dividends.
This table compares Glaukos Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Glaukos Corporation Competitors||-101.23%||-91.82%||-29.87%|
Valuation and Earnings
This table compares Glaukos Corporation and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Glaukos Corporation||$114.40 million||$4.52 million||-661.08|
|Glaukos Corporation Competitors||$1.67 billion||$207.58 million||77.52|
Glaukos Corporation’s competitors have higher revenue and earnings than Glaukos Corporation. Glaukos Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
93.1% of Glaukos Corporation shares are held by institutional investors. Comparatively, 57.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 16.4% of Glaukos Corporation shares are held by insiders. Comparatively, 11.2% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for Glaukos Corporation and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Glaukos Corporation Competitors||109||727||1024||10||2.50|
Glaukos Corporation currently has a consensus price target of $47.50, indicating a potential upside of 79.58%. As a group, “Medical Devices & Implants” companies have a potential upside of 34.97%. Given Glaukos Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe Glaukos Corporation is more favorable than its competitors.
Volatility & Risk
Glaukos Corporation has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Glaukos Corporation’s competitors have a beta of 0.81, indicating that their average share price is 19% less volatile than the S&P 500.
Glaukos Corporation beats its competitors on 10 of the 13 factors compared.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.